Forty-eight CIPN patients, who were hospitalized at the Oncology Department of the C University Hospital, were included in this study. The patients were assigned to the control (n = 24) and experimental groups (n = 24), alternately based on their order of registration. Inclusion criteria for stomach or colon cancer patients who were older than 18 years and who volunteered for this study were (1) patients receiving chemotherapy with a platinum agent or taxane; (2) patients receiving FOLFOX (folinic acid, leucovorin, fluorouracil, and oxaliplatin) regimen 3 times for 2 weeks and resting for 11 days; (3) patients with grade II or III sensory dimension of chronic idiopathic polyneuropathy (CIPN), using the National Cancer InstituteCommonToxicityCriteria (version 4.02); (4) patients who agreed to participate in the study (with informed
consent); and (5) patients without diabetes or disease of the neurological system and no metastasis to the brain.